Upjohn Company Profile
✉ Email this page to a colleague
What is the competitive landscape for UPJOHN
UPJOHN has thirteen approved drugs.
There are three US patents protecting UPJOHN drugs.
Summary for Upjohn
| US Patents: | 3 |
| Tradenames: | 12 |
| Ingredients: | 9 |
| NDAs: | 13 |
Drugs and US Patents for Upjohn
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upjohn | LYRICA CR | pregabalin | TABLET, EXTENDED RELEASE;ORAL | 209501-001 | Oct 11, 2017 | AB | RX | Yes | No | 9,144,559*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Upjohn | LYRICA | pregabalin | SOLUTION;ORAL | 022488-001 | Jan 4, 2010 | AA | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Upjohn | DETROL LA | tolterodine tartrate | CAPSULE, EXTENDED RELEASE;ORAL | 021228-002 | Dec 22, 2000 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Upjohn
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Upjohn | XANAX | alprazolam | TABLET;ORAL | 018276-001 | Approved Prior to Jan 1, 1982 | 4,508,726 | ⤷ Start Trial |
| Upjohn | XANAX XR | alprazolam | TABLET, EXTENDED RELEASE;ORAL | 021434-004 | Jan 17, 2003 | 5,061,494 | ⤷ Start Trial |
| Upjohn | XALATAN | latanoprost | SOLUTION/DROPS;OPHTHALMIC | 020597-001 | Jun 5, 1996 | 5,422,368 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for UPJOHN drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Capsules | 2 mg and 4 mg | ➤ Subscribe | 2007-07-30 |
| ➤ Subscribe | Capsules | 50 mg | ➤ Subscribe | 2008-03-21 |
| ➤ Subscribe | Oral Solution | 20 mg/mL | ➤ Subscribe | 2010-05-19 |
| ➤ Subscribe | Extended-release Tablets | 82.5 mg and 165 mg | ➤ Subscribe | 2018-02-02 |
| ➤ Subscribe | Extended-release Tablets | 82.5 mg and 165 mg | ➤ Subscribe | 2018-02-02 |
| ➤ Subscribe | Tablets | 20 mg and 40 mg | ➤ Subscribe | 2010-03-29 |
| ➤ Subscribe | Extended-release Tablets | 37.5 mg, 75 mg and 150 mg | ➤ Subscribe | 2007-05-03 |
| ➤ Subscribe | Capsules | 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg | ➤ Subscribe | 2008-12-30 |
| ➤ Subscribe | Extended-release Tablets | 330 mg | ➤ Subscribe | 2018-01-29 |
| ➤ Subscribe | Extended-release Tablets | 330 mg | ➤ Subscribe | 2018-01-29 |
| ➤ Subscribe | Tablets | 25 mg and 50 mg | ➤ Subscribe | 2006-09-27 |
International Patents for Upjohn Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Guatemala | 200600474 | ⤷ Start Trial |
| Spain | 2449231 | ⤷ Start Trial |
| Australia | 2006310217 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Upjohn Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0720599 | 92545 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ATORVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ATORVASTATINE SOUS FORME D'ATORVASTATINE CALCIQUE TRIHYDRATEE; FIRST REGISTRATION: 20140910 |
| 1003503 | 30/2006 | Austria | ⤷ Start Trial | PRODUCT NAME: AMLODIPIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SAEUREADDITIONSALZ DESSELBEN IN KOMBINATION MIT ATORVASTATIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DESSELBEN; NAT. REGISTRATION NO/DATE: 1-26271, 1-26273 20060330; FIRST REGISTRATION: FR 369300.9;369301.5; 369302.1;369303.8;369304.4;369305.0; 20050707 |
| 0641330 | C300164 | Netherlands | ⤷ Start Trial | PRODUCT NAME: PREGABALINE, DESGEWENST IN DE; REGISTRATION NO/DATE: EU/1/04/279/001 20040706 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
